Downloadable VYEPTI resource

Patient Discussion Guide

This guide includes helpful tips for discussing VYEPTI migraine prevention with your patients, including what they may expect from their IV treatment.

Downloadable VYEPTI resource

VYEPTI Infusion Checklist

Use this checklist to keep track of the complete VYEPTI dosing and administration process.

Downloadable VYEPTI resource

VYEPTI Antibody Science Review

Explore this brief overview of CGRP in migraine pathophysiology, and the science behind therapeutic antibodies, including the purposeful design of VYEPTI.

Downloadable VYEPTI resource

Eptinezumab-jjmr–The Purposeful Design

Discover the intentional design features of eptinezumab-jjmr.

Downloadable VYEPTI resource

PROMISE-1 Study

Explore the pivotal trial results for eptinezumab-jjmr in episodic migraine.

Downloadable VYEPTI resource

PROMISE-2 Study

Explore the pivotal trial results for eptinezumab-jjmr in chronic migraine.

Want updates when more resources become available?

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.